Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases
Central nervous system (CNS) metastases are associated with poor prognosis in patients with metastatic breast cancer (MBC). In this retrospective study, we investigated the activity of sacituzumab govitecan (SG) in 33 patients with HER2-negative MBC and CNS metastases, including active, stable/treated, and leptomeningeal disease (LMD). SG demonstrated a modest CNS objective response rate of 4/30 (13%) and median CNS-progression-free survival of 2.9 months (95%CI:2.0-4.3) in a heavily pretreated population.
Authors
- Sarah Sammons (ORCID: https://orcid.org/0000-0003-2589-9422)
- Melissa E. Hughes (ORCID: https://orcid.org/0000-0001-6190-9101)
- Antonio Giordano (ORCID: https://orcid.org/0000-0002-5959-016X)
- Thomas Grinda (ORCID: https://orcid.org/0000-0002-8567-9627)
- Liangge Hsu (ORCID: https://orcid.org/0000-0002-8806-3334)
- Tae-Kyung Yoo
- Nancy U. Lin (ORCID: https://orcid.org/0000-0003-2263-5413)
- Ayal A. Aizer (ORCID: https://orcid.org/0000-0002-8941-188X)
- Stefania Morganti (ORCID: https://orcid.org/0000-0001-5284-9944)
- José Pablo Leone (ORCID: https://orcid.org/0000-0002-8537-652X)
- Sara M. Tolaney (ORCID: https://orcid.org/0000-0002-5940-8671)
- Ross J. Kusmick
Institutions
- Ulsan College (KR)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Asan Medical Center (KR)
- Institut Gustave Roussy (FR)
- University of Ulsan (KR)
- Dana-Farber Cancer Institute (US)
- Dana-Farber Brigham Cancer Center (US)
Publication Details
- Journal
- npj Breast Cancer
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1038/s41523-025-00736-9
- Citations
- 10
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 13.67